We would love to hear your thoughts about our site and services, please take our survey here.
AS previously stated that Avacta can become the next Roche.
Roche AG
- Revenue £60Bn
- Market Cap £215Bn
Innovative development, partnerships, licencing deals and acquisitions are all part of the Avacta journey.
More news soon.
GLA
Several major developments and partnerships ongoing.
Those who are LTH’s, and researched, know the medical and commercial opportunity.
Current share price disappointing. STH’s lacking faith?
To quote another LTH, “Hold for Gold” :-)
GLA
July 2022 – Sierra Oncology, £1.5Bn
https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/
August 2022 - Affinivax, £2.7Bn
https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/
April 2023 - Bellus Health, £ 1.6Bn
https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-bellus-health/
There is activity within GSK.
GLA
Published: 8 May 2023
https://www.dailymail.co.uk/money/markets/article-12060487/Glaxo-hunt-takeover-targets.html
GSK growing their Drug and Oncology offerings through acquisition(s).
- Sierra Oncology (cancer drug maker) for £ 1.5billion.
- Affinivax (vaccine maker) for 2.7billion.
- Bellus Health (drugmaker) for £1.6billion.
GSK boss (Emma Walmsley) has confirmed that the group is hunting for more acquisitions as it looks to boost its pipeline of new drugs. ‘We are absolutely delighted with the deals we have announced in the last couple of months, we do intend to do more,’
‘There is more in the hopper, but obviously we cannot share details on that.’
GLA
DTW,
As you say, no bad news, only positive progress.
The scientific developments are revolutionary and life changing.
Leaders in their medical field(s) are getting on board.
One day, possibly very soon, .....
As ever, GLA
Doxorubicin (Dox’) has been used in the current form since the 1970’s. Dox’ is very good at treating cancer but the number of doses are restricted by the drugs toxicity.
5th September 2022
US FDA
AVA6000 granted Orphan Drug Designation.
https://avacta.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/
23rd February 2023
Dr William Tap
“If we have a version of Doxorubicin (AVA6000) that works better than the current offering then, overnight, that becomes the new standard of care”
27th April 2023
Move to Cohort 5, First patient dosed in USA with AVA6000
https://avacta.com/first-patient-dosed-in-the-us-in-avactas-ava6000-phase-1-clinical-study/
Doxorubicin Market Leaders, (Pfizer, J&J, Zydus, Cipla, Sun Pharma), know their market(s), the importance of Dox’, the opportunity to save many more lives and the commercial opportunities.
It may be licensing agreements, it may be an acquisition, but the market for life saving Dox’ will grow. The price to individually grow the market with Avacta is currently UK £ 320m, (Avacta market cap’).
Getting things done in Major Pharma’s takes time. Smaller, innovative companies can make decisions and innovations more quickly. That is Avacta, AVA6000, AVA3996 and many other innovative developments,
We may get major news soon, or it may take a little longer. Like most LTH’s, I am not for selling.
Sit tight, Hold and GLA
PS: Doxorubicin Market Leaders and Possible licensing partners,
Johnson and Johnson, Market Cap $ 510Bn
Pfizer Inc, Market Cap $ 231Bn
Zydus Group, Market Cap $ 6.5Bn
Cipla Limited, Market Cap $ 9.0Bn
Sun Pharmaceutical Industries Ltd, Market Cap $ 23.9Bn
@RAH - In full agreement.
We know that AVA6000 delivers the proven cancer drug (Dox’). Avacta has not yet found the AVA6000 MTD but we are already at x3 normal dosage of Dox’ with reduced side-effects. That is already a Big Win!
No one has offered a reason why AVA6000 will not work and you have asked several times.
As Dr. William Tap stated, “If we have a version of Doxorubicin (AVA6000) that works better than the current offering then, overnight, that becomes the new standard of care”. Dr. Tap is now on board in NY, USA.
The pre|CISION™ platform is open to so many other applications and treatments.
Big Pharma will be observing with interest and it is only a matter of time before a lucrative licence agreement(s) or an acquisition.
As you say, it’s a waiting game, …
GLA
The current trend is for Big Pharma to improve their oncology positions through either in-house development or acquisition.
Avacta’s AVA6000 and AVA3996 are offering very positive data and should both make considerable improvements to existing cancer treatments (Dox’) and outcomes.
Avacta has links with Big Pharma and many would have listened with interest at the recent AACR event.
1m shares traded by 09:00 yesterday and just over 2m for the whole day. 500K shares traded already this morning which, based on the share price, appear to be sells.
The current share price does not reflect the Avacta science and opportunity.
Stay with it, a BIG RNS could arrive at any time.
GLA
Interesting video presentation by AS this morning.
The current AVA6000 Dox levels are already x3 the norm.
Still working towards MTD, but we are already way ahead of current treatment levels with minimal side effects. What’s not to like?
GLA
Hello Bella,
I was going to add Launch Diagnostics (LD) but not sure how the group accounts will work at the moment. We will hopefully receive clarification next week.?
https://www.launchdiagnostics.com/about-us/
“Launch Diagnostics, part of the Avacta group, provides pathology solutions encompassing high quality diagnostic reagents and instrumentation”
- Turnover 2020 £ 26.9m / Profit £ 4.5m
- Turnover 2021 £ 29.2m / Profit £ 6.2m
LD Profits may be added to Avacta group accounts and help to balance current losses.
GLA
This is some of what we know:
5th September 2022
AVA6000 receives Orphan Drug Designation from FDA
https://avacta.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/
17th January 2023
Avacta successfully completed AVA6000 Cohort IV
https://avacta.com/avacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study/
5th April 2023
First patient(s) dosed in Cohort V with an increased dose at 250mg/m2
https://avacta.com/first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study/
6th April 2023
First two sites opened in USA for AVA6000 clinical investigation
https://avacta.com/avacta-opens-first-two-us-clinical-investigator-sites-for-ava6000-phase-1-clinical-study/
In addition,
16th April 2023
Avacta will present pre-clinical data on AVA3996 at the American Association of Cancer Research
https://avacta.com/avacta-to-present-pre-clinical-data-on-ava3996-at-the-american-association-for-cancer-research-annual-meeting/
25th April 2023
Interim results for 2022 reported increased revenue and reduction in losses
https://avacta.com/interim-results-for-the-period-ended-30-june-2022/
Avacta will present results for year ending December 2022 on 25th April 2023.
https://avacta.com/interim-results-for-the-period-ended-30-june-2022/
We will know more in the coming days and weeks.
So many opportunities for Avacta to change lives in so many ways.
Stay with it and GLA
And if there is a known expert in the oncology field, who is singing the praises of the new treatment, perhaps things can be brought forward for the benefit of those undergoing treatment(s)?
Dr. William Tap, 23rd Febraury 2023
“If we have a version of Doxorubicin (AVA6000) that works better than the current
offering then, overnight, that becomes the new standard of care”.
GLA
Valid comments RAH.
Reference, “Avacta’s Achilles heel has always been poor comms” , there has been 3 RNS statements this month so far.
Hopefully the communications message has now been received by Avacta.
3rd April 2023
https://avacta.com/notice-of-results-and-investor-presentation-5/
5th April 2023
https://avacta.com/first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study/
6th April 2023
https://avacta.com/avacta-opens-first-two-us-clinical-investigator-sites-for-ava6000-phase-1-clinical-study/
Who knows what the rest of April may bring?
Science Day - 23rd February 2023
Dr. William Tap:
"If we have a version of Doxorubicin (AVA6000) that works better than the current
offering then, overnight, that becomes the new standard of care".
Sorry to repeat but think it is very important.
GLA